Kotra Research Group is a multidisciplinary research group investigating at the intersection of medicinal chemistry, drug action, preformulations and pre/clinical studies. Kotra’s laboratory has successfully translated basic research into advanced preclinical and clinical studies. Over the past 20+ years, Kotra’s lab has maintained high standards to conduct cutting edge research, including various regulatory clearances to conduct research with controlled substances such as medical cannabis.
Current research programs in Kotra’s laboratory include chemical/preclinical/clinical research on medical cannabis, cannabinoids and CNS-acting agents such as psychadelic molecules including on various cellular and organ systems, antivirals in organ transplant, disease-modifying therapies targeting multiple sclerosis and neurodegenerative disorders, discovery of small molecules targeting thrombocytopenia, development of treatment strategies for chronic rhinosinusitis (CRS), and clinical development of Kopakamal as an antimalarial agent.
We are very proud of our collaborative network who are world-class, committed research groups to help advance the efforts towards meaningful clinical solutions.
One of the happy days in the lab Ewa, William, Rupali and Lakshmi
Dr. Lakshmi Kotra is the recipient of the Julia Levy Award 2020 from the Society of Chemical Industry (SCI Canada).
The Julia Levy Award is made in recognition of successful commercialisation of innovation in Canada, in the field of Bio-medical Science and Engineering. Dr Lakshmi Kotra inventions span novel small molecules for chronic diseases as well as novel industrial technologies, and several of them have been successful start-ups and further licensed for commercialization. Dr. Kotra has contributed to several drug discovery and drug delivery projects including anti-HIV drugs, antibacterials, insulin, antimalarials, drugs targeting multiple sclerosis, and medical cannabis-based therapeutics.
Connect with Dr. Kotra via Twitter and/or LinkedIn: